Mountain Valley MD (MVMD) AI Stock Analysis

• Market Cap: C$8.81M
• Dividend Yield: N/A
• Average Volume (3M): 99.68K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.02
• Revenue Growth: -48.33%
• EPS Growth: 47.56%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 352,354,950
• 10 Day Avg. Volume: 111,716
• 30 Day Avg. Volume: 99,679
• PEG Ratio: -0.04
• Price to Book (P/B): 1.15
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -2.09
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 35 Underperform
• Price Target: ―

Mountain Valley MD has a low overall score due to significant financial challenges, including negative profitability and cash flow issues. While a debt-free status is a positive aspect, the lack of strong revenue growth and profitability are major concerns. The technical analysis suggests a lack of strong momentum, and the valuation is unattractive due to the negative P/E ratio. The company needs to address its operational challenges to improve its financial health and stock performance.

Mountain Valley MD Business Overview & Revenue Model

Company Description

Mountain Valley MD (MVMD) is a biotechnology company focused on the development and commercialization of innovative health solutions. Operating primarily in the pharmaceutical and nutraceutical sectors, MVMD aims to advance medical technologies to improve global health outcomes. The company's core products and services include proprietary drug formulations, vaccine delivery systems, and nutraceutical products designed to enhance wellness and disease prevention.

How the Company Makes Money

Mountain Valley MD makes money through the commercialization of its proprietary health solutions. The company generates revenue from the sale of its pharmaceutical and nutraceutical products, leveraging its unique delivery systems and formulations. Additionally, MVMD may establish partnerships with other pharmaceutical firms to co-develop or license its technologies, which can provide significant revenue streams through licensing fees, royalties, and milestone payments. The company's focus on scalable and cost-effective solutions contributes to its earnings potential in both emerging and established markets.

Mountain Valley MD Financial Statement Overview

Summary

Mountain Valley MD faces significant financial challenges, with consistent losses, decreasing revenues, and negative cash flows. While the debt-free capital structure is a positive, the lack of profitability and cash generation poses substantial risks. Improvement in revenue streams and cost management is crucial for future stability.

Income Statement

Mountain Valley MD shows a concerning trend in its income statement with persistently negative net and gross profit margins. The TTM data indicates a gross loss and a significant net loss relative to revenues, suggesting challenges in revenue generation and cost management. Revenue growth has been erratic, with a decline from the previous annual report, indicating instability in business operations.

Balance Sheet

The balance sheet reflects a strong equity position with no debt, which is a positive aspect in terms of financial stability. However, the declining asset base and stockholders' equity over time raise concerns about the company's ability to sustain operations and growth. The equity ratio remains favorable, but the overall financial health is at risk if operational losses continue.

Cash Flow

The cash flow statement highlights significant negative free cash flow and operating cash flow, indicating liquidity issues and challenges in covering operational expenses. The absence of debt is a positive factor, but the consistent cash outflows could constrain future investments and operational scalability.

Breakdown	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	60.00K	0.00	110.00K	0.00	0.00
Gross Profit	-346.00K	-446.00K	70.00K	-430.19K	-52.16K
EBITDA	-3.19M	-6.89M	-9.29M	-7.57M	-18.51M
Net Income	-7.67M	-7.44M	-9.71M	-8.14M	-18.80M
Balance Sheet
Total Assets	8.97M	16.77M	25.27M	31.61M	12.23M
Cash, Cash Equivalents and Short-Term Investments	5.92M	9.71M	14.22M	19.51M	1.74M
Total Debt	0.00	6.00K	44.00K	84.50K	553.24K
Total Liabilities	258.00K	591.00K	422.00K	1.11M	3.68M
Stockholders Equity	8.71M	16.18M	24.85M	30.50M	8.55M
Cash Flow
Free Cash Flow	-3.80M	-4.85M	-5.68M	-4.31M	-3.74M
Operating Cash Flow	-3.30M	-4.79M	-5.59M	-3.86M	-2.98M
Investing Cash Flow	-503.00K	1.89M	-98.00K	-149.32K	-6.00M
Financing Cash Flow	0.00	-1.60M	395.00K	21.78M	1.63M

Mountain Valley MD Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:MVMD, the sentiment is Negative. The current price of 0.02 is below the 20-day moving average (MA) of 0.02, below the 50-day MA of 0.02, and below the 200-day MA of 0.02, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.56 is Neutral, neither overbought nor oversold. The STOCH value of >-0.01 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:MVMD.

Mountain Valley MD Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMCC	58 Neutral	$15.74M	―	-63.75%	―	12.68%	69.24%
MPH	57 Neutral	C$12.52M	―	-8.79%	―	-0.29%	-53.83%
Sector *	46 Neutral	C$201.68M	-3.23	-23.14%	1.87%	20.75%	-0.36%
RVV	46 Neutral	C$6.28M	―	-50.76%	―	―	-4.84%
MVMD	35 Underperform	C$8.81M	―	-44.58%	―	-48.33%	47.56%

Mountain Valley MD Corporate Events

Mountain Valley MD Advances Commercialization Strategies

Mountain Valley MD Holdings Inc. has advanced its commercialization strategies across its nutraceutical, agriculture, and husbandry animal sectors, aiming to enhance product efficacy and market reach. The company has strengthened its manufacturing and distribution partnerships, setting the stage for continued growth and increased revenues in 2025.